Remus Pharmaceuticals Limited — PPTs, 21-05-2026: Investor Presentation

Remus Pharmaceuticals posted solid FY26 consolidated results. Revenue jumped 37.6% year-on-year to INR 853.6 Cr, with profit after tax (PAT) growing 20.2% to INR 46.2 Cr. Diluted EPS was also up 20.2% at INR 39.19. The company operates on an asset-light model, leveraging a diverse portfolio of 900+ products, with 86% revenue from B2B and 14% from a growing B2C segment.

Growth is fueled by aggressive global expansion, especially into semi-regulated and emerging markets. Remus excels in quickly launching off-patent niche products and is planning 2,100 new product filings. The acquisition of Espee Global Holdings strengthens its US market presence and Reference Listed Drug (RLD) distribution capabilities. The company is also building its B2C Relius brand, with 26 product launches in Bolivia and 40 more planned.

Recent operational wins include securing government tenders in Nicaragua, Saudi Arabia, and North Macedonia. Remus expanded its oncology, urology, and anti-infective portfolios, and strategically entered the anti-obesity segment with Semaglutide filings. The outlook emphasizes deepening its Latin American presence and expanding into Eastern Europe, Africa, and ASEAN regions.